HIVManagement.org

 
Quick Menu / Table of Contents
Introduction Principles Management NRTI Info NNRTI Info
PI Info Fusion Inhibitors Drug Summary Investigational Adherence
Lab Evaluation Resistance Tests PEP Antiretroviral Tables OI Prevention
Vaccinations TB Therapy Hepatitis Therapy OI Diagnosis OI Therapy
Bibliography Links Palliative Therapy

 

Truvada
emtricitabine + tenofovir

Detailed Prescribing Information

October 2005

 

Truvada
A combination of tenofovir + emtricitabine
Approved 8-2-2004
Forms Available 300 mg tenofovir / 200 mg emtricitabine in tablet form
Dosing 1 tablet once a day with or without food
Renal dosing Dosing interval
Ccr 30-49 cc/min
Dosing interval
Ccr < 30 cc/min
48 hours Not recommended
Hepatic dosing: very little data, but preliminary information suggests little effect on dosing.
Food dependence None significant.
Adverse Effects Same as tenofovir and emtricitabine (see above or click on the drug name)
Interactions Same as tenofovir and emtricitabine (see above or click on the drug name)
Suggested lab follow-up Monthly CBC for 3 months, then every 3 months if stable
Consider monthly creatinine measurements in lean individuals or those with renal insufficiency.
Warning

Rare lactic acidosis and hepatic steatosis.
Do not used fixed dose combination in persons with renal insufficiency.
Severe acute exacerbations of chronic hepatitis B may be observed with sudden discontinuation of Truvada.

Contraindication None

Suggested Usage

Do not use in combination with lamivudine, emtricitabine, Epzicom, Combivir, or Trizivir due to identical mechanism of action or duplication of emtricitabine dosing.

Complete prescribing information

Truvada Prescribing Info
Also see http://www.truvada.com for further info as it becomes available.

 

 

Next Page Click HERE for Key NRTI Information or Antiretroviral Summary Information


 

Links to Antiretroviral Sections (click on anything)
Nucleoside & Nucleotide Reverse Transcriptase Inhibitors (NRTI)
AZT  |  ddC  |  ddI  |  d4T  |  3TC  |  ABC  |  FTC  |  TDF  |  Combivir  |  Trizivir  |  Epzicom  |  Truvada  |  Atripla
Nonnucleoside Reverse Transcriptase Inhibitors (NNRTI)
efavirenz  |  nevirapine  |  delavirdine
Protease Inhibitors (PI)  |  Boosted Protease Inhibitors
saquinavir  indinavir  |  ritonavir  |  nelfinavir  |  amprenavir  |  lopinavir + ritonavir  |  atazanavir  |  fosamprenavir  | tipranavir  |  darunavir
Fusion Inhibitors
enfuvirtide
 
Quick Menu / Table of Contents
Introduction Principles Management NRTI Info NNRTI Info
PI Info Fusion Inhibitors Drug Summary Investigational Adherence
Lab Evaluation Resistance Tests PEP Antiretroviral Tables OI Prevention
Vaccinations TB Therapy Hepatitis Therapy OI Diagnosis OI Therapy
Bibliography Links Palliative Therapy

 

 

Updated 10.25.2005

 


 

1. Renal dosing information from: Ian R. McNicholl & Rudolph A. Rodriguez, MD, Dosing of Antiretroviral Drugs in Renal Insufficiency and Hemodialysis, May 2004
http://hivinsite.ucsf.edu/InSite?page=md-rr-18